Multi-billion dollar IP dispute exposes dangers of life sciences collaborations
Seattle Genetics is demanding rights to Daiichi Sankyo’s potential blockbuster cancer treatment, which it says is an improvement on the proprietary technology included in their previous partnership
To read more
Register for limited access
Register to receive our weekly newsletter and access two of our subscriber-only articles per month.
Subscribe and start reading now
Subscribe for unlimited access to articles, in-depth analysis and research from the IAM experts.